{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:10:34Z","timestamp":1788952234871,"version":"build-2803163510"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008092","name":"Jinhua Science and Technology Bureau","doi-asserted-by":"publisher","award":["Grant No. 2023-3-100 to C.C."],"award-info":[{"award-number":["Grant No. 2023-3-100 to C.C."]}],"id":[{"id":"10.13039\/501100008092","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant PD-1\/PD-L1 combined with chemoradiotherapy (CRT) has shown encouraging complete response (CR) rates in proficient mismatch repair (pMMR) or microsatellite-stable (MSS) locally advanced rectal cancer (LARC), yet immunotherapy duration varies widely across trials and its interaction with radiotherapy fractionation remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane Library were searched through October 8, 2025 for prospective trials of PD-1\/PD-L1 inhibitors plus CRT in pMMR\/MSS LARC. Random-effects models pooled CR (cCR+pCR) rates, with subgroup analyses and study-level meta-regression conducted to explore sources of heterogeneity. A linear probit model and an interactive quadratic probit model were applied to assess associations between treatment duration and response (PROSPERO number CRD420251253156).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighteen trials (972 patients; 10 LCRT-based and 8 SCRT-based) were included. Pooled CR and pCR rates were 44% (95%\n                      <jats:italic>CI<\/jats:italic>\n                      0.38\u20130.49) and 40% (95%\n                      <jats:italic>CI<\/jats:italic>\n                      0.36\u20130.45). CR was higher with SCRT plus ICI than LCRT plus ICI (50% vs 39%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.03), and pCR similarly favored SCRT (47% vs 34%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.01). Meta-regression identified radiotherapy fractionation and immunotherapy duration as study-level factors associated with CR. In analyses restricted to randomized controlled trials (RCTs), longer immunotherapy duration was positively associated with response. Exploratory quadratic models using all eligible studies suggested an inverted U-shaped pattern for LCRT (modeled peak at approximately 4.4 months) and a U-shaped pattern for SCRT (modeled trough at approximately 2.5 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among the included RCTs, longer immunotherapy duration was associated with higher response rates. The nonlinear patterns observed in the combined dataset were exploratory, may reflect heterogeneity between studies, and require prospective validation before informing treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261348026<\/jats:ext-link>\n                      , identifier CRD420251253156.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1855615","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:17:27Z","timestamp":1788949047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonlinear duration\u2013efficacy association of neoadjuvant PD-1\/PD-L1 blockade with chemoradiotherapy in pMMR\/MSS locally advanced rectal cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Shuyang","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shicheng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ba","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Colorectal and Anal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2210175","article-title":"Prevalence of mismatch-repair deficiency in rectal adenocarcinomas","volume":"387","author":"Papke","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.Cd-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31078-x","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability\u2013high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1786","article-title":"The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)","volume":"34","author":"Capdevila Castillon","year":"2023","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.099","article-title":"Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2","volume":"40","author":"George","year":"2022","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101824","article-title":"Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial","volume":"8","author":"Grassi","year":"2023","journal-title":"ESMO Open"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.241","article-title":"Adebrelimab combined with short-course radiotherapy and CAPOX as total neoadjuvant therapy for pMMR locally advanced rectal cancer: Interim results","volume":"36","author":"Jing","year":"2025"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.e15621","article-title":"Phase II trial of anti PD-1 monoclonal antibody and FOLFOXIRI combined with longcourse radiotherapy as the total neoadjuvant treatment for proficient mismatch repair, locally advanced, low rectal cancer (PANFORTE)","volume":"43","author":"Peng","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100807","article-title":"Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II)","volume":"6","author":"Tang","year":"2025","journal-title":"Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00286-4","article-title":"Total neoadjuvant treatment with short-course radiotherapy followed by sintilimab plus capecitabine\u2013oxaliplatin versus short-course radiotherapy followed by capecitabine\u2013oxaliplatin in patients with locally advanced rectal cancer (SPRING-01): a single-centre, open-label, phase 2, randomised controlled trial","volume":"26","author":"Tian","year":"2025","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03360-5","article-title":"Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial","volume":"31","author":"Yang","year":"2025","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115428","article-title":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study","volume":"222","author":"Shamseddine","year":"2025","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001960","article-title":"Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg (London England)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-024-01762-y","article-title":"Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.e15602","article-title":"Preliminary efficacy and safety of total neoadjuvant therapy combined with PD-L1 blockade in pMMR\/MSS locally advanced rectal cancer (ESTIMATE): A prospective, single-arm, phase II trial","volume":"42","author":"Zhang","year":"2024"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2409154","article-title":"The duration of immunotherapy for mismatch repair-deficient cancers","volume":"392","author":"Rousseau","year":"2025","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1186\/s12885-025-14482-5","article-title":"Neoadjuvant chemoradiotherapy with or without PD-1\/PD-L1 inhibitors in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"25","author":"Ansab","year":"2025","journal-title":"BMC Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.111073","article-title":"Neoadjuvant immunotherapy and chemoradiotherapy for mismatch repair proficient locally advanced rectal cancer: a systematic review and meta-analysis","volume":"211","author":"Wang","year":"2025","journal-title":"Radiother Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-16-1673","article-title":"Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade","volume":"23","author":"Dovedi","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2024.00052","article-title":"Lymphopenia is an adverse prognostic factor in rectal adenocarcinoma patients receiving long-course chemoradiotherapy","volume":"42","author":"Koukourakis","year":"2024","journal-title":"Radiat Oncol J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.207","article-title":"Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation","volume":"4","author":"Kono","year":"2013","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1554018","article-title":"High-dose radiation induces dendritic cells maturation by promoting immunogenic cell death in nasopharyngeal carcinoma","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"Anz J Surg"},{"key":"B44","article-title":"Cochrane handbook for systematic reviews of interventions version 6.5 (updated august 2024)","author":"Higgins","year":"2024"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.27769","article-title":"Dual immune checkpoint inhibition plus neoadjuvant chemoradiotherapy in rectal cancer: a randomized clinical trial","volume":"8","author":"Laengle","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.120","article-title":"Opportunities and challenges of radiotherapy for treating cancer","volume":"12","author":"Schaue","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00325","article-title":"Combinations of immunotherapy and radiation in cancer therapy","volume":"4","author":"Vatner","year":"2014","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:17:30Z","timestamp":1788949050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1855615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":52,"alternative-id":["10.3389\/fonc.2026.1855615"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1855615","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1855615"}}